Cited by 942Cytokine Signaling Pathways and InteractionsImmunodeficiency and Autoimmune DisordersNF-κB Signaling Pathways

The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

Open access

O'Shea, John J., Holland, Steven M., Staudt, Louis M.·2013·New England Journal of Medicine

DOI 10.1056/nejmra1202117PMC PMC7604876

Open this paper in CoChat — free account

Abstract

A large number of cytokines signal through the JAK–STAT pathway. Abnormal function of this pathway may lead to a variety of diseases. Targeting the defects in this signaling pathway has already led to treatment advances, and further advances are likely.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmra1202117

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAKS AND STATS: Biological Implications
Leonard, W. J., & O’Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,826
Self-citation
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596

Show all 101 references

Research works printed but not linked: 1

10.1172/JCI0215617 · DOI

Sorted by citations

The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
Harding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S. M., Gray, A. J. G., Bruce, L., Alexander, S. P. H., Anderton, S. M., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1121 · Cited by 1,650
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O’Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. D. J. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,670
Self-citation
Activated STING in a Vascular and Pulmonary Syndrome
Liu, Y., de Jesus, A. A., Marrero, B., Yang, D., RAMSEY, S. E., Sanchez, G. A. M., Tenbrock, K., Wittkowski, H., Jones, O. Y., Kuehn, H. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312625 · Cited by 1,415
Self-citation
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Self-citation
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G. R., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 799
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Chen, X., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 797
Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination
Furman, D., Hejblum, B. P., Simon, N., Jojic, V., Dekker, C. L., Thiébaut, R., Tibshirani, R. J., & Davis, M. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321060111 · Cited by 700
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Self-citation
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 583
Erratum to: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Banerjee, S., Biehl, A. J., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 592
Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations
Milner, J. D., Vogel, T. P., Forbes, L. R., Ma, C. A., Stray‐Pedersen, A., Niemela, J. E., Lyons, J. J., Engelhardt, K. R., Zhang, Y., Topcagic, N., et al. (2014) · Blood · doi:10.1182/blood-2014-09-602763 · Cited by 569
Mechanisms of Jak/STAT Signaling in Immunity and Disease
Villarino, A. V., Kanno, Y., Ferdinand, J. R., & O’Shea, J. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401867 · Cited by 564
Self-citation
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501
Self-citation
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Therapeutic modulators of STAT signalling for human diseases
Miklóssy, G., Hilliard, T. S., & Turkson, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4088 · Cited by 418
Th2 Cells in Health and Disease
Nakayama, T., Hirahara, K., Onodera, A., Endo, Y., Hosokawa, H., Shinoda, K., Tumes, D. J., & Okamoto, Y. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052350 · Cited by 412
Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A. V., Ward, M. M., Gadina, M., & O’Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.267 · Cited by 402
Self-citation
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
Olivera, P. A., Lasa, J. S., Bonovas, S., Danese, S., & Peyrin‐Biroulet, L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.001 · Cited by 336
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
Coskun, M., Salem, M. A., Pedersen, J., & Nielsen, O. H. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.007 · Cited by 334
Current and future status of JAK inhibitors
McLornan, D. P., Pope, J. E., Gotlib, J. R., & Harrison, C. N. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00438-4 · Cited by 336
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“This pathway is activated in response to many protein ligands, including cytokines, growth factors, interferons (IFNs), and peptide hormones, where it regulates a wide range of cellular processes, including cell growth, proliferation, differentiation, and apoptosis (Rawlings et al., 2004; O’Shea et al., 2013).”
Background
Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition
Groner, B., & von Manstein, V. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.033 · Cited by 308
Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008824 · Cited by 307
Emerging cell and cytokine targets in rheumatoid arthritis
Burmester, G. R., Feist, E., & Dörner, T. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.168 · Cited by 308
The surface topography of silicone breast implants mediates the foreign body response in mice, rabbits and humans
Doloff, J. C., Omid Veiseh, A., de Mezerville, R., Sforza, M., Perry, T. A., Haupt, J. L., Jamiel, M., Chambers, C., Nash, A., Aghlara-Fotovat, S., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00739-4 · Cited by 305
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
Hurwitz, H. I., Uppal, N., Wagner, S. A., Bendell, J. C., Beck, J. T., Wade, S., Nemunaitis, J. J., Stella, P. J., Pipas, J. M., Wainberg, Z. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.4578 · Cited by 302
Fragile X-associated tremor/ataxia syndrome — features, mechanisms and management
Hagerman, R. J., & Hagerman, P. J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.82 · Cited by 293
Alternatively activated macrophages; a double-edged sword in allergic asthma
Abdelaziz, M. H., Abdelwahab, S. F., Wan, J., Cai, W., Wang, H., Cheng, J., Kesavan, D. K., Vasudevan, A., Sadek, A., Su, Z., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02251-w · Cited by 289
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P., Lee, C. H., Fidelus-Gort, R., Luchi, M., Rooney, T. P., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206478 · Cited by 282
Tofacitinib Citrate for the Treatment of Vitiligo
Craiglow, B. G., & King, B. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1520 · Cited by 262
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T. P., Chen, L., Dickson, C. L., Camp, J. R., Cardillo, T. E., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.171361 · Cited by 258
Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis
Xue, X., Ramakrishnan, S. K., Weisz, K. M., Triner, D. A., Xie, L., Attili, D., Pant, A., Győrffy, B., Zhan, M., Carter‐Su, C., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.015 · Cited by 247
Review: The Interleukin‐23/Interleukin‐17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond
Smith, J. A., & Colbert, R. A. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38291 · Cited by 252
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
Harrington, R., Nokhatha, S. A. A., & Conway, R. P. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s219586 · Cited by 241
Curcumin: a modulator of inflammatory signaling pathways in the immune system
Kahkhaie, K. R., Mirhosseini, A., Aliabadi, A., Mohammadi, A., Mousavi, M. J., Haftcheshmeh, S. M., Sathyapalan, T., & Sahebkar, A. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00607-3 · Cited by 242
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Rompaey, L. V., Galien, R., van der Aar, E. M., Clément-Lacroix, P., Nelles, L., Smets, B., Lepescheux, L., Christophe, T., Conrath, K., Vandeghinste, N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201348 · Cited by 235
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma
Tiacci, E., Ladewig, E., Schiavoni, G., Penson, A., Fortini, E., Pettirossi, V., Wang, Y., Rosseto, A. S., Venanzi, A., Vlasevska, S., et al. (2018) · Blood · doi:10.1182/blood-2017-11-814913 · Cited by 244
Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review
Ayele, T. M., Muche, Z. T., Teklemariam, A. B., Bogale, A., & Abebe, E. C. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s353489 · Cited by 231
The Jak/STAT pathway: A focus on pain in rheumatoid arthritis
Simon, L. S., Taylor, P. C., Choy, E., Sebba, A. I., Quebe, A. K., Knopp, K. L., & Porreca, F. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.10.008 · Cited by 222
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Levy, L., Urban, J. R., & King, B. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.06.045 · Cited by 215
Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Bruno, A., Mortara, L., Baci, D., Noonan, D. M., & Albini, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00771 · Cited by 223
Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment
Dey, P., Li, J., Zhang, J., Chaurasiya, S., Strom, A., Wang, H., Liao, W.-T., Cavallaro, F., Denz, P., Bernard, V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0297 · Cited by 213
“It is well established that ligand-induced dimerization of cytokine receptors leads to cross-phosphorylation of tyrosine residues in JAKs, which in turn interact with the SH2 domain of the STAT transcription factors, leading to STAT phosphorylation, homodimerization, and activation (18).”
Background
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
Hasni, S., Gupta, S., Davis, M., Poncio, E., Temesgen‐Oyelakin, Y., Carlucci, P. M., Wang, X., Naqi, M., Playford, M. P., Goel, R. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23361-z · Cited by 204
Self-citation
Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin
Zhang, L., & Wang, H. (2015) · Marine Drugs · doi:10.3390/md13074310 · Cited by 202
Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies
Li, H., Boulougoura, A., Endo, Y., & Tsokos, G. C. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102870 · Cited by 211
Neuroimmune communication regulating pruritus in atopic dermatitis
Steinhoff, M. S., Ahmad, F., Pandey, A. K., Datsi, A., AlHammadi, A., Al‐Khawaga, S., Al-Malki, A., Meng, J., Alam, M. A., & Buddenkotte, J. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.03.010 · Cited by 201
The Role of STAT3 in Non-Small Cell Lung Cancer
Harada, D., Takigawa, N., & Kiura, K. (2014) · Cancers · doi:10.3390/cancers6020708 · Cited by 195
Cancers Related to Immunodeficiencies: Update and Perspectives
Mortaz, E., Tabarsi, P., Mansouri, D., Khosravi, A., Garssen, J., Velayati, A. A., & Adcock, I. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00365 · Cited by 195
Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation
Glassman, C. R., Tsutsumi, N., Saxton, R. A., Lupardus, P. J., Jude, K. M., & García, K. C. (2022) · Science · doi:10.1126/science.abn8933 · Cited by 186
The complex STATes of astrocyte reactivity: How are they controlled by the JAK-STAT3 pathway?
Ceyzériat, K., Abjean, L., Carrillo-de Sauvage, M.-A., Ben Haim, L., & Escartin, C. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.05.043 · Cited by 185
Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy
Waldmann, T. A., & Chen, J. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-110416-120628 · Cited by 173
Methotrexate Is a JAK/STAT Pathway Inhibitor
Thomas, S. J., Fisher, K. H., Snowden, J. A., Danson, S. J., Brown, S., & Zeidler, M. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130078 · Cited by 169
2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications
González, N., Prieto, I., del Puerto‐Nevado, L., Portal‐Núñez, S., Ardura, J. A., Cortón, M., Fernández‐Fernández, B., Aguilera, Ó., Gómez‐Guerrero, C., Mas, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14472 · Cited by 177
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Bonelli, M. M., Kerschbaumer, A., Kastrati, K., Ghoreschi, K., Gadina, M., Heinz, L. X., Smolen, J. S., Aletaha, D., O’Shea, J. J., & Laurence, A. D. J. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-223850 · Cited by 185
Self-citation
Next generation of small molecules in inflammatory bowel disease
Olivera, P., Danese, S., & Peyrin-Biroulet, L. (2017) · Gut · doi:10.1136/gutjnl-2016-312912 · Cited by 154
Mechanisms underlying helper T-cell plasticity: Implications for immune-mediated disease
Hirahara, K., Poholek, A. C., Vahedi, G., Laurence, A. D. J., Kanno, Y., Milner, J. D., & O’Shea, J. J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.03.015 · Cited by 171
Self-citation
Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase
Shan, Y., Gnanasambandan, K., Ungureanu, D., Kim, E. T., Hammarén, H. M., Yamashita, K., Silvennoinen, O., Shaw, D. E., & Hubbard, S. R. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2849 · Cited by 162
Sex differences in the late first trimester human placenta transcriptome
Gonzalez, T. L., Sun, T., Koeppel, A. F., Lee, B., Wang, E. T., Farber, C. R., Rich, S. S., Sundheimer, L. W., Buttle, R. A., Chen, Y.-D. I., et al. (2018) · Biology of Sex Differences · doi:10.1186/s13293-018-0165-y · Cited by 169
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Gadina, M., Johnson, C., Schwartz, D. M., Bonelli, M. M., Hasni, S., Kanno, Y., Changelian, P. S., Laurence, A. D. J., & O’Shea, J. J. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0218-084r · Cited by 162
Self-citation
The Ying and Yang of STAT3 in Human Disease
Vogel, T. P., Milner, J. D., & Cooper, M. A. (2015) · Journal of Clinical Immunology · doi:10.1007/s10875-015-0187-8 · Cited by 166
STAT3 Hyper-IgE Syndrome—an Update and Unanswered Questions
Tsilifis, C., Freeman, A. F., & Gennery, A. R. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01051-1 · Cited by 162
Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation
Weinacht, K. G., Charbonnier, L., Alroqi, F. J., Plant, A., Qiao, Q., Wu, H., Ma, C., Torgerson, T. R., Rosenzweig, S. D., Fleisher, T. A., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.11.022 · Cited by 159
Berberine as a natural modulator of inflammatory signaling pathways in the immune system: Focus on NF‐κB , JAK / STAT , and MAPK signaling pathways
Haftcheshmeh, S. M., Abedi, M., Mashayekhi, K., Mousavi, M. J., Navashenaq, J. G., Mohammadi, A., & Momtazi‐Borojeni, A. A. (2022) · Phytotherapy Research · doi:10.1002/ptr.7407 · Cited by 161
Intervertebral disc degeneration—Current therapeutic options and challenges
Samanta, A., Lufkin, T., & Kraus, P. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1156749 · Cited by 168
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Hornung, T., Janzen, V., Heidgen, F.-J., Wolf, D. G. F., Bieber, T. R. M., & Wenzel, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1412997 · Cited by 156
Immunity against fungi
Lionakis, M. S., Iliev, I. D., & Hohl, T. M. (2017) · JCI Insight · doi:10.1172/jci.insight.93156 · Cited by 153
Inflammatory cytokines in human pancreatic cancer
Roshani, R., McCarthy, F. M., & Hagemann, T. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.014 · Cited by 160
Therapeutic Targeting of the JAK / STAT Pathway
Aittomäki, S., & Pesu, M. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12164 · Cited by 152
Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells
Khan, M. N., Maryam, A., Qazi, J. I., & Ma, T. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.11595 · Cited by 148
JAK inhibitors and infections risk: focus on herpes zoster
Sunzini, F., McInnes, I., & Siebert, S. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20936059 · Cited by 150
The JAK-STAT pathway: from structural biology to cytokine engineering
Lv, Y., Qi, J., Babon, J. J., Cao, L., Fan, G.-H., Lang, J., Zhang, J., Mi, P., Kobe, B., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01934-w · Cited by 157
Intersection of mTOR and STAT signaling in immunity
Saleiro, D., & Platanias, L. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.10.006 · Cited by 142
Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy
Bosch‐Barrera, J., & Menéndez, J. A. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.008 · Cited by 139
Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
Wathes, R., Moule, S., & Milojković, D. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302135 · Cited by 137
Advances in targeted therapy for malignant lymphoma
Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 146
Back to the future: oral targeted therapy for RA and other autoimmune diseases
O'Shea, J. J., Laurence, A., & McInnes, I. B. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.7 · Cited by 115
Self-citation
Targeting the JAK/STAT pathway in solid tumors
Qureshy, Z., Johnson, D. E., & Grandis, J. R. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.58 · Cited by 133
Mutant Prolactin Receptor and Familial Hyperprolactinemia
Newey, P. J., Gorvin, C. M., Cleland, S. J., Willberg, C. B., Bridge, M., Azharuddin, M. K., Drummond, R. S., van der Merwe, P. A., Klenerman, P., Bountra, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307557 · Cited by 132
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Menet, C. J., Fletcher, S. R., Lommen, G. V., Geney, R., Blanc, J., Smits, K., Jouannigot, N., Deprez, P., van der Aar, E. M., Clément-Lacroix, P., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501262q · Cited by 131
Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
Ferreira, S., Guttman‐Yassky, E., & Torres, T. R. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00548-6 · Cited by 128
STATs get their move on
Reich, N. C. (2013) · JAK-STAT · doi:10.4161/jkst.27080 · Cited by 131
Pathogenesis of myeloproliferative neoplasms
Skoda, R. C., Duek, A., & Grisouard, J. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.06.007 · Cited by 135
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition
Luo, Y., Alexander, M. T., Gadina, M., O’Shea, J. J., Meylan, F., & Schwartz, D. M. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.004 · Cited by 121
Self-citation
OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
Kim, M., Nam, H.-J., Kim, H., Han, S., Im, S., Kim, T., Oh, D., & Bang, Y. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.010 · Cited by 117
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
Vries, L. C. S. D., Wildenberg, M. E., de Jonge, W. J., & D’Haens, G. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx003 · Cited by 118
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Smolen, J. S., Kremer, J. M., Gaich, C. L., DeLozier, A. M., Schlichting, D. E., Xie, L., Stoykov, I., Rooney, T. P., Bird, P., Bursón, J. M. S., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209821 · Cited by 114
The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications
Wang, X., Chen, L., Wei, J., Zheng, H., Zhou, N., Xu, X., Deng, X., Liu, T., & Zou, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02220-z · Cited by 132
The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy
Yuan, W., Zhao, Q., Gao, Z., Lao, X., Lin, W., Chen, D., Mu, M., Huang, C.-X., Liu, Z., Li, B., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127726 · Cited by 114
Targeting STAT3 with silibinin to improve cancer therapeutics
Bosch‐Barrera, J., Queralt, B., & Menéndez, J. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.003 · Cited by 112
Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent
Xiang, M. H., Kim, H. T., Ho, V. T., Walker, S. R., Bar‐Natan, M., Anahtar, M., Liu, S., Toniolo, P. A., Kroll, Y., Jones, N., et al. (2016) · Blood · doi:10.1182/blood-2015-07-660506 · Cited by 110
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
Damsky, W., Peterson, D. M., Ramseier, J. Y., Al‐Bawardy, B., Chun, H. J., Proctor, D. D., Strand, V., Flavell, R. A., & King, B. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.022 · Cited by 115
Activation of the JAK/STAT pathway in Behcet’s disease
Virlan, A. T., Dozmorov, M. G., Özdemir, F. T., Yilmaz, V., Ekşioğlu, E., Alıbaz-Öner, F., Özen, G., Wren, J. D., Saruhan‐Direskeneli, G., Sawalha, A. H., et al. (2014) · Genes and Immunity · doi:10.1038/gene.2014.64 · Cited by 106
An Activating STAT3 Mutation Causes Neonatal Diabetes through Premature Induction of Pancreatic Differentiation
Saarimäki‐Vire, J., Balboa, D., Russell, M. A., Saarikettu, J., Kinnunen, M., Keskitalo, S., Malhi, A., Valensisi, C., Andrus, C. R., Eurola, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.055 · Cited by 105
Main path and byways: non‐vesicular glutamate release by system xc−as an important modifier of glutamatergic neurotransmission
Massie, A., Boillée, S., Hewett, S. J., Knackstedt, L. A., & Lewerenz, J. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13348 · Cited by 106
The Epigenetic Regulator G9a Mediates Tolerance to RNA Virus Infection in Drosophila
Merkling, S. H., Bronkhorst, A. W., Kramer, J. M., Overheul, G. J., Schenck, A., & van Rij, R. P. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004692 · Cited by 97
Cross talk of tyrosine kinases with the DNA damage signaling pathways
Mahajan, K. N., & Mahajan, N. P. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1166 · Cited by 101

Authors: O'Shea, J. J., Holland, S. M., & Staudt, L. M.
Affiliations: National Institute of Allergy and Infectious Diseases (US)
National Institutes of Health (US)
ORCID: Holland, Steven M.
Staudt, Louis M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-01-10
Volume: 368
Issue: 2
Pages: 161-170
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra1202117
PMC: PMC7604876
OpenAlex: W2040002852
Cited by: 927
References: 101
Citations by year: 2026: 47 · 2025: 61 · 2024: 64 · 2023: 76 · 2022: 79 · 2021: 91 · 2020: 78 · 2019: 60 · 2018: 44 · 2017: 70 · 2016: 66 · 2015: 69 · 2014: 67 · 2013: 52
FWCI: 8.98
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01SC004024)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (ZIAAR041106)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Keywords: JAK/STAT signaling, cytokine signaling, immunodeficiency, cancer, immune regulation, JAK inhibitors, STAT inhibitors, targeted therapy
MeSH terms: Hematologic Diseases, Humans, Immunologic Deficiency Syndromes, Mutation, Neoplasms, Signal Transduction, Cytokines, STAT Transcription Factors, Janus Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks